Targeting FAP in human cancer patients with the humanized monoclonal antibody sibrotuzumab, which shows high affinity for binding to FAP [98], or the FAP enzyme inhibitor talabostat [99], which has not demonstrated clinical efficacy in NSCLC patients. This evidence concerns the gene FAP and cancer.